Abstract Number: 667 • 2017 ACR/ARHP Annual Meeting
Urinary Metabolomic Fingerprint As Diagnostic Biomarker for Clinical Significant Lupus Nephritis
-Background/Purpose: Lupus nephritis (LN) represents the main prognostic factor in systemic lupus erythematosus (LES) [1]. The clinical significant classes of LN –due to the need…Abstract Number: 668 • 2017 ACR/ARHP Annual Meeting
Is Uric Acid Level a Predictor of Long-Term Renal Outcome in Lupus Nephritis?
Background/Purpose: Hyperuricemia has been reported to be associated with chronic kidney disease (CKD) in several clinical conditions, and recent studies also observed an association between…Abstract Number: 669 • 2017 ACR/ARHP Annual Meeting
Unbiased Screening of Urinary Protein Biomarkers for Glomerular Filtration Rate Normalization
Background/Purpose: To account for glomerular filtration rate, urinary creatinine is routinely used for the normalization of urine biomarkers related to disease. Because of the small…Abstract Number: 670 • 2017 ACR/ARHP Annual Meeting
Membrane Attack Complex (MAC) Deposition in Lupus Nephritis Is Associated with Hypertension and Poor Clinical Response to Treatment
Background/Purpose: LN is characterized by deposition of immune complexes in the kidney. Activation of the classical complement pathway by dsDNA is believed to play a…Abstract Number: 671 • 2017 ACR/ARHP Annual Meeting
A New Histological Index for Predicting a Decline in Kidney Function in Patients with Lupus Nephritis. a Mexican Cohort Study of 186 Patients with a Kidney Biopsy
- Background/Purpose: The NIH indexes (of activity and chronicity) were proposed by Austin et al., in 1984. At the moment, there are therapies which can…Abstract Number: 672 • 2017 ACR/ARHP Annual Meeting
Baseline Hyperuricemia As a Predictive Value for Development of Lupus Nephritis in Premenopausal SLE Patients
Background/Purpose: Although lupus nephritis is a common and serious manifestation of SLE, there have been few predictive markers for development of lupus nephritis in SLE…Abstract Number: 673 • 2017 ACR/ARHP Annual Meeting
Cell Bound Complement Activation Products Distinguish Systemic Lupus Erythematosus from Other Diseases Among Patients with High Antinuclear Antibody Titers and Normal Complement
Background/Purpose: Patients are often referred to the rheumatologist because of elevated anti-nuclear antibody (ANA) titers. We sought to evaluate the association of cell bound complement…Abstract Number: 674 • 2017 ACR/ARHP Annual Meeting
Identification of IRAK4-Dependent Gene Signature As a Biomarker Candidate for IRAK4 Small-Molecule Inhibitor in Systemic Lupus Erythematosus
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a heterogeneous disease. Interleukin-1 receptor-associated kinase 4 (IRAK4) activity is predicted to affect multiple pathogenic pathways in SLE1. We…Abstract Number: 675 • 2017 ACR/ARHP Annual Meeting
Tissue-Based Biomarkers in Cutaneous Lupus Erythematosus: Type I IFN Responsive Protein Mxa and a Marker for Lymphocytic Inflammation (CD45) Correlate with CLASI Cross-Sectionally and Longitudinally
Background/Purpose: Cutaneous lupus erythematosus (CLE) is the cutaneous manifestation of SLE, affecting 85% of patients1. CLE is subdivided into acute, subacute and chronic/discoid forms. Discoid…Abstract Number: 676 • 2017 ACR/ARHP Annual Meeting
Immunosignature Autoantibody Profiles Provide Mechanistic Insight into Systemic Lupus Erythematosus and Differentiation from Symptomatically Overlapping Diseases
Background/Purpose: Diagnosis and monitoring of patients with SLE usually requires careful evaluation by a rheumatologist. However, difficulties in accurately quantifing disease and treatment response can…Abstract Number: 677 • 2017 ACR/ARHP Annual Meeting
Soluble Urokinase Plasminogen Activator Receptor (suPAR) Predicts the Development of Organ Damage over 5 Years in Systemic Lupus Erythematosus: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Background/Purpose: The urokinase plasminogen activator receptor (uPAR) is expressed on various cell types and plays important roles in proteolysis, migration and adhesion. Receptor shedding yields…Abstract Number: 678 • 2017 ACR/ARHP Annual Meeting
Systemic Hypertension Is Associated with Presence of Vascular Injury on Lupus Nephritis Renal Biopsies: A Retrospective Cohort Study
Background/Purpose: Vascular injury in lupus nephritis is often described on renal biopsy, but its clinical correlates are not well understood. Recent evidence suggests it may…Abstract Number: 679 • 2017 ACR/ARHP Annual Meeting
Distinct Interferon Scores Are Separately Associated with Activity and Long Term Sequelae in SLE
Background/Purpose: Type I interferon (IFN-I) has a crucial role in the pathogenesis and activity of Systemic Lupus Erythematosis (SLE). IFN-I targeted therapies are currently in…Abstract Number: 680 • 2017 ACR/ARHP Annual Meeting
Abnormalities in Complement System Are Related to Disease Severity in Systemic Lupus Erythematosus (SLE)
Background/Purpose: We sought to evaluate the relationships between low complement C3 and C4 proteins, abnormal complement activation (cell-bound complement activation products [CB-CAPs]), and a Lupus…Abstract Number: 681 • 2017 ACR/ARHP Annual Meeting
A Panel of Lupus Biomarkers for the Monitoring of Systemic Lupus Erythematosus: Performance Characteristics in Distinct SLE Cohorts
Background/Purpose: Antibody titers to double stranded DNA (anti-dsDNA) and complement C3 and C4 proteins have clinical utility in the routine monitoring of systemic lupus erythematosus…
ACR Meeting Abstracts